Quinn Opportunity Partners’s Avadel Pharmaceuticals AVDL Stock Holding History

Quinn Opportunity Partners’s Portfolio AVDL Stock Details AVDL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-14,028	Closed	-$302K	–	365
2025 Q4	$302K	Sell	14,028 -4,972	-26%	-$96.5K	0.01%	316
2025 Q3	$290K	Sell	19,000 -11,100	-37%	-$144K	0.02%	271
2025 Q2	$266K	Hold	30,100	–	–	0.02%	283
2025 Q1	$236K	Buy	+30,100	New	+$252K	0.02%	323

Other funds holding AVDL

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

Quinn Opportunity Partners's AVDL Position: Q1 2026 in Review

Quinn Opportunity Partners sold out of Avadel Pharmaceuticals (AVDL) in Q1 2026, closing a stake of 14,028 shares — an estimated $302K sold.

Quinn Opportunity Partners first reported a position in AVDL in Q1 2025 and held it in 4 quarters. The position peaked at $302K in Q4 2025. 2 funds tracked by Wall St. Rank hold AVDL as of Q1 2026.

Quinn Opportunity Partners reported no remaining Avadel Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Quinn Opportunity Partners sold 14,028 Avadel Pharmaceuticals shares in Q1 2026, an estimated $302K.
Quinn Opportunity Partners first reported a position in Avadel Pharmaceuticals in Q1 2025 and held it in 4 quarters.
Quinn Opportunity Partners's Avadel Pharmaceuticals position peaked at $302K in Q4 2025.
2 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2026.

Based on Quinn Opportunity Partners's 13F filing for Q1 2026, filed 15 May 2026.